Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient
                    Management in Increased-Risk Thyroid Cancer

Rendl, Gundula; Rettenbacher, Lukas; Schweighofer-Zwink, Gregor; Hehenwarter, Lukas; Pirich, Christian

doi:10.1055/a-1111-8927

Cited by 4 publications

(1 citation statement)

References 35 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior 131 I scanning is an alternative, and concerns that this may lead to a greater risk of 'stunning' compared with 123 I scanning, and therefore to the reduced therapeutic efficacy of the ablation administration, appear unfounded [10]. 18 F FDG (fluorodeoxyglucose) PET CT (computed tomography) is an alternative diagnostic imaging technique which can be used prior to remnant for risk stratification, to facilitate a more personalised approach [11].…”

Section: Differentiated Thyroid Cancermentioning

confidence: 99%

Personalisation of Molecular Radiotherapy through Optimisation of Theragnostics

Davis

Smith

Aldridge

et al. 2020

JPM

View full text Add to dashboard Cite

Molecular radiotherapy, or targeted radionuclide therapy, uses systemically administered drugs bearing a suitable radioactive isotope, typically a beta emitter. These are delivered via metabolic or other physiological pathways to cancer cells in greater concentrations than to normal tissues. The absorbed radiation dose in tumour deposits causes chromosomal damage and cell death. A partner radiopharmaceutical, most commonly the same vector labelled with a different radioactive atom, with emissions suitable for gamma camera or positron emission tomography imaging, is used to select patients for treatment and to assess response. The use of these pairs of radio-labelled drugs, one optimised for therapy, the other for diagnostic purposes, is referred to as theragnostics. Theragnostics is increasingly moving away from a fixed number of defined activity administrations, to a much more individualised or personalised approach, with the aim of improving treatment outcomes, and minimising toxicity. There is, however, still significant scope for further progress in that direction. The main tools for personalisation are the following: imaging biomarkers for better patient selection; predictive and post-therapy dosimetry to maximise the radiation dose to the tumour while keeping organs at risk within tolerance limits; imaging for assessment of treatment response; individualised decision making and communication about radiation protection, adjustments for toxicity, inpatient and outpatient care.

show abstract

Section: Differentiated Thyroid Cancermentioning

confidence: 99%